133 related articles for article (PubMed ID: 38720354)
1. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
de Luca Montes RA; Huq M; Godfrey T; Oon S; Calderone A; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Jan Wu YJ; Golder V; Lateef A; Navarra SV; Zamora L; Hamijoyo L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Chan M; Goldblatt F; O'Neill S; Lau CS; Cho J; Hoi A; Karyekar CS; Morand EF; Nikpour M
Adv Rheumatol; 2024 May; 64(1):38. PubMed ID: 38720354
[TBL] [Abstract][Full Text] [Related]
2. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
Zen M; Saccon F; Gatto M; Montesso G; Larosa M; Benvenuti F; Iaccarino L; Doria A
Rheumatology (Oxford); 2020 Jul; 59(7):1591-1598. PubMed ID: 31642908
[TBL] [Abstract][Full Text] [Related]
4. Interventions for cutaneous disease in systemic lupus erythematosus.
Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
[TBL] [Abstract][Full Text] [Related]
5. Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults.
Edwards Mayhew RG; Li T; McCann P; Leslie L; Strong Caldwell A; Palestine AG
Cochrane Database Syst Rev; 2022 Oct; 10(10):CD014831. PubMed ID: 36315029
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.
Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
Clin Rheumatol; 2019 Oct; 38(10):2785-2791. PubMed ID: 31175481
[TBL] [Abstract][Full Text] [Related]
7. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort.
Mok CC; Tse SM; Chan KL; Ho LY
Lupus; 2018 Apr; 27(5):722-727. PubMed ID: 29087260
[TBL] [Abstract][Full Text] [Related]
8. Association of patient copayment and medication adherence in systemic lupus erythematosus.
Lomanto Silva R; Swabe GM; Sattui SE; Magnani JW
Lupus Sci Med; 2023 Oct; 10(2):. PubMed ID: 37852670
[TBL] [Abstract][Full Text] [Related]
9. Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus.
Nakai T; Fukui S; Kidoguchi G; Ikeda Y; Kitada A; Nomura A; Tamaki H; Kishimoto M; Okada M
Clin Rheumatol; 2022 Dec; 41(12):3735-3745. PubMed ID: 35939162
[TBL] [Abstract][Full Text] [Related]
10. Update οn the diagnosis and management of systemic lupus erythematosus.
Fanouriakis A; Tziolos N; Bertsias G; Boumpas DT
Ann Rheum Dis; 2021 Jan; 80(1):14-25. PubMed ID: 33051219
[TBL] [Abstract][Full Text] [Related]
11. Systemic lupus erythematosus: review of synthetic drugs.
Tsang-A-Sjoe MW; Bultink IE
Expert Opin Pharmacother; 2015; 16(18):2793-806. PubMed ID: 26479437
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
Kan H; Nagar S; Patel J; Wallace DJ; Molta C; Chang DJ
Clin Ther; 2016 Mar; 38(3):610-24. PubMed ID: 26907503
[TBL] [Abstract][Full Text] [Related]
13. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T
Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824
[TBL] [Abstract][Full Text] [Related]
14. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
[TBL] [Abstract][Full Text] [Related]
15. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.
Ordi-Ros J; Sáez-Comet L; Pérez-Conesa M; Vidal X; Mitjavila F; Castro Salomó A; Cuquet Pedragosa J; Ortiz-Santamaria V; Mauri Plana M; Cortés-Hernández J
Ann Rheum Dis; 2017 Sep; 76(9):1575-1582. PubMed ID: 28450313
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
[TBL] [Abstract][Full Text] [Related]
17. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
18. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
[TBL] [Abstract][Full Text] [Related]
19. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis A; Kostopoulou M; Andersen J; Aringer M; Arnaud L; Bae SC; Boletis J; Bruce IN; Cervera R; Doria A; Dörner T; Furie RA; Gladman DD; Houssiau FA; Inês LS; Jayne D; Kouloumas M; Kovács L; Mok CC; Morand EF; Moroni G; Mosca M; Mucke J; Mukhtyar CB; Nagy G; Navarra S; Parodis I; Pego-Reigosa JM; Petri M; Pons-Estel BA; Schneider M; Smolen JS; Svenungsson E; Tanaka Y; Tektonidou MG; Teng YO; Tincani A; Vital EM; van Vollenhoven RF; Wincup C; Bertsias G; Boumpas DT
Ann Rheum Dis; 2024 Jan; 83(1):15-29. PubMed ID: 37827694
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
Petri M; Magder LS
Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
